Astellas Beats Lupin, Zydus Bid to Nix Myrbetriq ER Patent (1)

Astellas Pharma Inc. defeated two generic-drug makers’ key invalidity defenses over a patent for Myrbetriq ER in a long-running clash over copycat versions of the overactive-bladder treatment.

Lupin Ltd. and Zydus Lifesciences Ltd. failed to prove that US Patent No. 10,842,780 is invalid, according to Judge Joseph F. Bataillon’s findings of fact and conclusions of law issued Tuesday in the US District Court for the District of Delaware. Infringement, damages, and any additional invalidity arguments remain for a jury trial next year, Batallion said.

Bataillon, a senior judge sitting by designation from the District of Nebraska, on Tuesday rejected a ...